BAJAJ BROKING

Notification close image
No new Notification messages
card image
Smartworks Coworking Spaces IPO is Open!
Apply for the Smartworks Coworking Spaces IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

9540

200519

SAKAR

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SAKAR HEALTHCARE LIMITED performance

Today’s low

Today’s high

₹ 346.50 ₹ 350.00
₹ 346.90

52 week low

52 week high

₹ 210.10 ₹ 380.80
₹ 346.90

Open Price

₹ 348.60

Prev. Close

₹ 346.90

Volume (Shares)

14574.00

Total traded value

₹ 50.55

Upper Circuit

₹ 364.20

Lower Circuit

₹ 329.55

info

SAKAR HEALTHCARE LIMITED Share Price Update

As of the latest trading session, SAKAR HEALTHCARE LIMITED share price is currently at ₹ 348.1, which is up by ₹ 1.20 from its previous closing. Today, the stock has fluctuated between ₹ 346.50 and ₹ 350.00. Over the past year, SAKAR HEALTHCARE LIMITED has achieved a return of 3.82 %. In the last month alone, the return has been 9.51 %. Read More...

Investment Returns

Over 1 Month 9.51% Over 3 Months 45.53% Over 6 Months 19.27% Over 1 Year 3.82%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

SAKAR HEALTHCARE LIMITED fundamentals


  • Market cap (Cr)

    761.40

  • P/E Ratio (TTM)

    44.10

  • Beta

    0.58

  • Book Value / share

    130.09

  • Return on equity

    5.36%

  • EPS (TTM)

    7.99

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    5.76

info icon alternate text
  • Market cap (Cr)

    0.0

  • P/E Ratio (TTM)

    0.0

  • Beta

    0.0

  • Book Value / share

    0.0

  • Return on equity

    0.0%

  • EPS (TTM)

    0.0

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.0

info icon alternate text

SAKAR HEALTHCARE LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 50.24
Operating Expense 44.18
Net Profit 5.76
Net Profit Margin (%) 11.46
Earnings Per Share (EPS) 2.66
EBITDA 15.91
Effective Tax Rate (%) 7.69
Particulars DEC 2024 (Values in Cr)
Revenue 43.42
Operating Expense 38.19
Net Profit 4.53
Net Profit Margin (%) 10.43
Earnings Per Share (EPS) 2.08
EBITDA 12.01
Effective Tax Rate (%) 17.15
Particulars SEP 2024 (Values in Cr)
Revenue 42.78
Operating Expense 38.04
Net Profit 4.80
Net Profit Margin (%) 11.22
Earnings Per Share (EPS) 2.17
EBITDA 11.87
Effective Tax Rate (%) 6.06
Particulars JUN 2024 (Values in Cr)
Revenue 41.15
Operating Expense 36.91
Net Profit 2.41
Net Profit Margin (%) 5.85
Earnings Per Share (EPS) 1.10
EBITDA 11.16
Effective Tax Rate (%) 48.72
Particulars MAR 2024 (Values in Cr)
Revenue 43.06
Operating Expense 39.04
Net Profit 3.12
Net Profit Margin (%) 7.24
Earnings Per Share (EPS) 1.46
EBITDA 11.75
Effective Tax Rate (%) 34.79
Particulars MAR 2025 (Values in Cr)
Revenue 177.58
Operating Expense 157.32
Net Profit 17.50
Net Profit Margin (%) 9.85
Earnings Per Share (EPS) 7.97
EBITDA 50.95
Effective Tax Rate (%) 18.71
Particulars MAR 2024 (Values in Cr)
Revenue 153.35
Operating Expense 140.63
Net Profit 11.67
Net Profit Margin (%) 7.61
Earnings Per Share (EPS) 5.64
EBITDA 41.54
Effective Tax Rate (%) 26.60
Particulars MAR 2023 (Values in Cr)
Revenue 133.36
Operating Expense 121.15
Net Profit 12.76
Net Profit Margin (%) 9.56
Earnings Per Share (EPS) 6.58
EBITDA 37.82
Effective Tax Rate (%) 24.40
Particulars MAR 2022 (Values in Cr)
Revenue 128.23
Operating Expense 111.39
Net Profit 15.24
Net Profit Margin (%) 11.88
Earnings Per Share (EPS) 8.77
EBITDA 31.58
Effective Tax Rate (%) 19.83
Particulars MAR 2021 (Values in Cr)
Revenue 94.74
Operating Expense 82.67
Net Profit 10.69
Net Profit Margin (%) 11.28
Earnings Per Share (EPS) 6.88
EBITDA 23.78
Effective Tax Rate (%) 19.25
Particulars MAR 2024 (Values in Cr)
Book Value / Share 118.41
ROE % 5.36
ROCE % 7.36
Total Debt to Total Equity 0.46
EBITDA Margin 27.09
Particulars MAR 2023 (Values in Cr)
Book Value / Share 91.04
ROE % 8.48
ROCE % 8.85
Total Debt to Total Equity 0.70
EBITDA Margin 28.35
Particulars MAR 2022 (Values in Cr)
Book Value / Share 74.45
ROE % 13.49
ROCE % 12.05
Total Debt to Total Equity 0.60
EBITDA Margin 24.63
Particulars MAR 2021 (Values in Cr)
Book Value / Share 63.04
ROE % 11.88
ROCE % 13.07
Total Debt to Total Equity 0.33
EBITDA Margin 25.09
Particulars MAR 2020 (Values in Cr)
Book Value / Share 54.35
ROE % 11.83
ROCE % 14.68
Total Debt to Total Equity 0.20
EBITDA Margin 25.99
Particulars MAR 2024 (Values in Cr)
Book Value / Share 118.44
ROE % 5.36
ROCE % 7.36
Total Debt to Total Equity 0.46
EBITDA Margin 27.09
Particulars MAR 2023 (Values in Cr)
Book Value / Share 91.09
ROE % 8.48
ROCE % 8.85
Total Debt to Total Equity 0.70
EBITDA Margin 28.35
Particulars MAR 2022 (Values in Cr)
Book Value / Share 74.50
ROE % 13.49
ROCE % 12.05
Total Debt to Total Equity 0.60
EBITDA Margin 24.63
Particulars MAR 2021 (Values in Cr)
Book Value / Share 63.04
ROE % 11.89
ROCE % 13.07
Total Debt to Total Equity 0.33
EBITDA Margin 25.10
Particulars MAR 2020 (Values in Cr)
Book Value / Share 54.35
ROE % 12.57
ROCE % 15.91
Total Debt to Total Equity 0.18
EBITDA Margin 25.99
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.46
Total Assets 388.65
Total Liabilities 388.65
Total Equity 262.33
Share Outstanding 21750000
Price to Book Ratio 3.11
Return on Assets (%) 3.00
Return on Capital (%) 3.52
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 336.33
Total Liabilities 336.33
Total Equity 173.34
Share Outstanding 19040000
Price to Book Ratio 2.20
Return on Assets (%) 3.79
Return on Capital (%) 4.48
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 267.76
Total Liabilities 267.76
Total Equity 127.46
Share Outstanding 17118000
Price to Book Ratio 1.81
Return on Assets (%) 5.66
Return on Capital (%) 7
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.08
Total Assets 177.79
Total Liabilities 177.79
Total Equity 98.45
Share Outstanding 15618000
Price to Book Ratio 1.79
Return on Assets (%) 6.00
Return on Capital (%) 7.71
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.29
Total Assets 115.03
Total Liabilities 115.03
Total Equity 81.31
Share Outstanding 14961000
Price to Book Ratio 0.92
Return on Assets (%) 8.36
Return on Capital (%) 10.03
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.46
Total Assets 388.74
Total Liabilities 388.74
Total Equity 262.41
Share Outstanding 21750000
Price to Book Ratio 3.11
Return on Assets (%) 3.00
Return on Capital (%) 3.52
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 336.42
Total Liabilities 336.42
Total Equity 173.43
Share Outstanding 19040000
Price to Book Ratio 2.20
Return on Assets (%) 3.79
Return on Capital (%) 4.48
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 267.84
Total Liabilities 267.84
Total Equity 127.53
Share Outstanding 17118000
Price to Book Ratio 1.81
Return on Assets (%) 5.69
Return on Capital (%) 7.02
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.08
Total Assets 177.80
Total Liabilities 177.80
Total Equity 98.46
Share Outstanding 15618000
Price to Book Ratio 1.79
Return on Assets (%) 6.01
Return on Capital (%) 7.71
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.29
Total Assets 115.12
Total Liabilities 115.12
Total Equity 81.31
Share Outstanding 14961000
Price to Book Ratio 0.92
Return on Assets (%) 8.35
Return on Capital (%) 10.02
Particulars MAR 2024 (Values in Cr)
Net Income 15.89
Cash from Operations 141.82
Cash from Investing -51.53
Cash from Financing 27.44
Net change in Cash 0.37
Free Cash Flow 201.38
Particulars MAR 2023 (Values in Cr)
Net Income 16.87
Cash from Operations 37.60
Cash from Investing -74.37
Cash from Financing 41.09
Net change in Cash 0.06
Free Cash Flow 119.80
Particulars MAR 2022 (Values in Cr)
Net Income 19.00
Cash from Operations 35.52
Cash from Investing -90.37
Cash from Financing 54.62
Net change in Cash -0.05
Free Cash Flow 133.05
Particulars MAR 2021 (Values in Cr)
Net Income 13.23
Cash from Operations 15.30
Cash from Investing -46.83
Cash from Financing 32.03
Net change in Cash -0.22
Free Cash Flow 62.13
Particulars MAR 2020 (Values in Cr)
Net Income 12.22
Cash from Operations 21.63
Cash from Investing -22.40
Cash from Financing 3.48
Net change in Cash -0.06
Free Cash Flow 43.68
Particulars MAR 2024 (Values in Cr)
Net Income 15.89
Cash from Operations 141.82
Cash from Investing -51.53
Cash from Financing 27.44
Net change in Cash 0.37
Free Cash Flow 201.38
Particulars MAR 2023 (Values in Cr)
Net Income 16.87
Cash from Operations 37.60
Cash from Investing -74.37
Cash from Financing 41.09
Net change in Cash 0.06
Free Cash Flow 119.80
Particulars MAR 2022 (Values in Cr)
Net Income 19.00
Cash from Operations 35.59
Cash from Investing -90.40
Cash from Financing 54.56
Net change in Cash -0.05
Free Cash Flow 133.12
Particulars MAR 2021 (Values in Cr)
Net Income 13.24
Cash from Operations 15.31
Cash from Investing -46.83
Cash from Financing 32.03
Net change in Cash -0.21
Free Cash Flow 62.14
Particulars MAR 2020 (Values in Cr)
Net Income 12.22
Cash from Operations 21.56
Cash from Investing -22.33
Cash from Financing 3.48
Net change in Cash -0.07
Free Cash Flow 43.53
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.19 32.03 1.98 277.34 34.11 / 77.70
BLISS GVS PHARMA LTD 155.40 19.45 1.56 1638.62 105.05 / 184.95
CIPLA LTD 1491.80 23.42 3.86 120493.85 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 356.25 13.64 2.88 1048.48 189.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.19 92.79 5.71 277.34 34.11 / 77.70
AMRUTAJAN HEALTH LTD 717.40 40.81 6.35 2074.05 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 9296.00 132.76 30.16 23240.00 6222.35 / 10653.05
BLISS GVS PHARMA LTD 155.40 23.76 1.54 1638.62 105.05 / 184.95

SAKAR HEALTHCARE LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
346.90 -1.30 redarrow
red-green-graph indicator
7 Bearish
9 Bullish
  • 5 Days 349.80
  • 26 Days 340.90
  • 10 Days 349.90
  • 50 Days 325.30
  • 12 Days 349.30
  • 100 Days 308.30
  • 20 Days 345.00
  • 200 Days 304.40
351.65 PIVOT

First Support

344.85

First Resistance

358.30

Second Support

338.20

Second Resistance

365.10

Third Support

331.40

Third Resistance

371.75

RSI

59.33

ADX

38.88

MACD

8.41

Williams % R

-52.99

Commodity Channel Index (CCI)

26.69

Date

2025-06-26

Week

35813.00

Same Day

31990.00

Month

22111.00

1 Year

0.59

3 Year

0.68

Over 1 Month

9.51%

down

Over 1 Year

3.82%

down

Over 3 Months

45.53%

down

Over 3 Years

28.60%

down

Over 6 Months

19.27%

down

Over 5 Years

41.92%

down

SAKAR HEALTHCARE LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
32.81%
Promoter Holdings
53.58%
FII
13.6%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Sanjay S Shah 1.0008543E7 (45.6%) Shareholding of Promoter and Promoter Group
Tata Capital Healthcare Fund Ii 2309910.0 (10.52%) Public Shareholding
Hbm Healthcare Investments (cayman) Ltd 1500000.0 (6.83%) Public Shareholding
Cobra India (mauritius) Limited 1418886.0 (6.46%) Public Shareholding
Shah Aarsh 1407500.0 (6.41%) Shareholding of Promoter and Promoter Group
Hi-tech Chemicals Limited 429699.0 (1.96%) Public Shareholding
Ritaben Shah 245000.0 (1.12%) Shareholding of Promoter and Promoter Group
Shah Ayushi 100000.0 (0.46%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

SAKAR HEALTHCARE LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

SAKAR HEALTHCARE LIMITED Share Price

Sakar Healthcare Limited was incorporated as a Private Limited Company under the name 'Sakar Healthcare Private Limited on 26th March 2004. Subsequently, the Company was converted into Public Limited Company on March 27, 2015 and the name of the Company was changed to 'Sakar Healthcare Limited. The Company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah.

The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections and Oral Solid Dossages. It manufactures and markets pharmaceutical formulations relating to analgesics, anti coagulants, anti malarial, anti spasmodic, antianemics, antibiotics, anti-emetics, anti-histamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.

The Company operates as contract development and manufacturing organisation (CDMO), being the EU GMP approved CMO for leading multinational pharmaceutical companies.Their 4 manufacturing facilities located at Changodar, Ahmedabad, Gujarat. have been approved by various international regulatory authorities and certified by ISO 9001:2008 (BVQI), WHO-GMP, CGMP & National Drug Authority, and it has obtained certain drug specific registrations from the relevant authorities in countries such as Uganda, Kenya, Yemen, Ethiopia, Congo, Ghana, Zimbabwe, Namibia, Nigeria, Cote d'ivoire.

In 2005, the Company started commercial production for Plant - 1 which was established for production of Liquid Orals; in 2007, it started exporting its products overseas; started commercial production for Plant - 2 which was established for production of Beta Lactum Tablet and Capsules and Dry Syrup B-lactum. / Sachet in 2008. Further, it started commercial production for Plant - 3 which was established for production of Liquid Injectibles (SVP) - Ampoules and Liquid Injectibles (SVP) - Vials.

In 2012, it started commercial production for Plant - 4 which was established for production of Dry Powder Injection. In 2017, it started Lyophilised injection product commercialisation.

In 2020, the Company received EU GMP certification for SVP unit manufacturing liquid and Lyophilised injections. In 2021, the Oncology Unit started operations in Bavla location. In 2022-23, the Company started commercialization with Oncology product post receiving WHO GMP certification.

Parent organization Indian Private
NSE symbol SAKAR
Founded 2004
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Sakar Healthcare Ltd?

Answer Field

Sakar Healthcare Ltd share price is for NSE ₹ 348.10 & for BSE ₹ 0.00 as on Jul 11 2025 10:21 AM.

What is the Market Cap of Sakar Healthcare Ltd Share?

Answer Field

The market cap of Sakar Healthcare Ltd for NSE ₹ 757.11 & for BSE ₹ 0.00 as on Jul 11 2025 10:21 AM.

What is the 52 Week High and Low of Sakar Healthcare Ltd?

Answer Field

The 52 Week High and Low of Sakar Healthcare Ltd for NSE is ₹ 380.80 and ₹ 210.10 and for BSE is ₹ 0.00 and ₹ 0.00.

What is 1 year return for Sakar Healthcare Ltd?

Answer Field

The 1 year returns on the stock has been 3.82%.

What is the P/E Ratio of Sakar Healthcare Ltd Share?

Answer Field

As on Jul 11 2025 10:21 AM the price-to-earnings (PE) ratio for Sakar Healthcare Ltd share is 44.10.

What is the PB ratio of Sakar Healthcare Ltd Share?

Answer Field

As on Jul 11 2025 10:21 AM, the price-to-book (PB) ratio for Sakar Healthcare Ltd share is 130.09.

How to Buy Sakar Healthcare Ltd Share?

Answer Field

You can trade in Sakar Healthcare Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Sakar Healthcare Ltd Share on Bajaj Broking App?

Answer Field

To buy Sakar Healthcare Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Sakar Healthcare Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|